Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:57:28.177Z.
Calculation as of: 2026-10-06T17:57:28.177Z.
Quote observation: 2026-10-06T17:37:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a92f25166a0617989281a7eefd332dc08894ee274fcedbd674fe1a92e2c9d78d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$10.51M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.56M
Price/OCF Ratio
N/A
TTM Avg
5.31
3Y Avg
5.31
5Y Avg
5.31
Market Cap
$10.08M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Satellos Bioscience Inc. (MSLE) | $10.37M | N/A | N/A | N/A | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.30M | N/A | N/A | N/A | N/A |
| Valion Bio, Inc. (VBIO)vs › | $10.15M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.52M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.56M | N/A | 5.31 | 5.31 | 5.31 |
| Pluri Inc. (PLUR)vs › | $10.59M | N/A | N/A | N/A | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.59M | N/A | N/A | N/A | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.08M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
